Galectin-1 Protein Therapy Prevents Pathology and Improves Muscle Function in the mdx Mouse Model of Duchenne Muscular Dystrophy

Molecular Therapy

Volumn 23, Issue 8, 2015, Pages 1285-1297

  Van Ry, Pam M ^a   Wuebbles, Ryan D ^a   Key, Megan ^a   Burkin, Dean J ^a  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA7 INTEGRIN; ALPHA7BETA1 INTEGRIN; BETA DYSTROGLYCAN; GALECTIN 1; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UTROPHIN; DYSTROGLYCAN; INTEGRIN; INTEGRIN ALPHA7BETA1; LGALS1 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DUCHENNE MUSCULAR DYSTROPHY; HUMAN; HUMAN CELL; KYPHOSIS; MOUSE; MUSCLE CELL; MUSCLE CONTRACTION; MUSCLE FUNCTION; MUSCLE STRENGTH; NONHUMAN; SARCOLEMMA; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; CELL LINE; DISEASE MODEL; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; MUSCULAR DYSTROPHY, DUCHENNE; PATHOPHYSIOLOGY; SKELETAL MUSCLE;

CANIS FAMILIARIS; MUS;

ANIMALS; CELL LINE; DISEASE MODELS, ANIMAL; DYSTROGLYCANS; EXTRACELLULAR MATRIX; GALECTIN 1; HUMANS; INTEGRINS; MICE; MICE, INBRED MDX; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; RECOMBINANT PROTEINS; SARCOLEMMA; UTROPHIN;

EID: 84938420530     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.105     Document Type: Article

References (54)

1. Davies, KE, Smith, TJ, Bundey, S, Read, AP, Flint, T, Bell, M et al. (1988). Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome. J Med Genet 25: 9-13.
2. Campbell, KP (1995). Three muscular dystrophies: loss of cytoskeleton-extracellular matrix linkage. Cell 80: 675-679.
3. Senter, L, Luise, M, Presotto, C, Betto, R, Teresi, A, Ceoldo, S et al. (1993). Interaction of dystrophin with cytoskeletal proteins: binding to talin and actin. Biochem Biophys Res Commun 192: 899-904.
4. Suzuki, A, Yoshida, M, Hayashi, K, Mizuno, Y, Hagiwara, Y and Ozawa, E (1994). Molecular organization at the glycoprotein-complex-binding site of dystrophin. Three dystrophin-associated proteins bind directly to the carboxy-terminal portion of dystrophin. Eur J Biochem 220: 283-292.
5. Ohlendieck, K, Ervasti, JM, Snook, JB and Campbell, KP (1991). Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. J Cell Biol 112: 135-148.
6. Leppänen, A, Stowell, S, Blixt, O and Cummings, RD (2005). Dimeric galectin-1 binds with high affnity to alpha2, 3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem 280: 5549-5562.
7. Camby, I, Le Mercier, M, Lefranc, F and Kiss, R (2006). Galectin-1: a small protein with major functions. Glycobiology 16: 137R-157R.
8. Cedeno-Laurent, F and Dimitroff, CJ (2012). Galectin-1 research in T cell immunity: past, present and future. Clin Immunol 142: 107-116.
9. Cerri, DG, Rodrigues, LC, Stowell, SR, Araujo, DD, Coelho, MC, Oliveira, SR et al. (2008). Degeneration of dystrophic or injured skeletal muscles induces high expression of Galectin-1. Glycobiology 18: 842-850.
10. Chan, J, O'Donoghue, K, Gavina, M, Torrente, Y, Kennea, N, Mehmet, H et al. (2006). Galectin-1 induces skeletal muscle differentiation in human fetal mesenchymal stem cells and increases muscle regeneration. Stem Cells 24: 1879-1891.
11. Goldring, K, Jones, GE, Thiagarajah, R and Watt, DJ (2002). The effect of galectin-1 on the differentiation of fbroblasts and myoblasts in vitro. J Cell Sci 115(Pt 2): 355-366.
12. Goldring, K, Jones, GE, Sewry, CA and Watt, DJ (2002). The muscle-specifc marker desmin is expressed in a proportion of human dermal fbroblasts after their exposure to galectin-1. Neuromuscul Disord 12: 183-186.
13. Georgiadis, V, Stewart, HJ, Pollard, HJ, Tavsanoglu, Y, Prasad, R, Horwood, J et al. (2007). Lack of galectin-1 results in defects in myoblast fusion and muscle regeneration. Dev Dyn 236: 1014-1024.
14. Gu, M, Wang, W, Song, WK, Cooper, DN and Kaufman, SJ (1994). Selective modulation of the interaction of alpha 7 beta 1 integrin with fbronectin and laminin by L-14 lectin during skeletal muscle differentiation. J Cell Sci 107 (Pt 1): 175-181.
15. Grossi, A, Lametsch, R, Karlsson, AH and Lawson, MA (2011). Mechanical stimuli on C2C12 myoblasts affect myoblast differentiation, focal adhesion kinase phosphorylation and galectin-1 expression: a proteomic approach. Cell Biol Int 35: 579-586.
16. McDonald, CM, Henricson, EK, Abresch, RT, Florence, JM, Eagle, M, Gappmaier, E et al.; PTC124-GD-007-DMD Study Group. (2013). The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study. Muscle Nerve 48: 343-356.
17. Laws, N and Hoey, A (2004). Progression of kyphosis in mdx mice. J Appl Physiol (1985) 97: 1970-1977.
18. Karol, LA (2007). Scoliosis in patients with Duchenne muscular dystrophy. J Bone Joint Surg Am 89 Suppl 1: 155-162.
19. Okano, K, Tsuruta, Y, Yamashita, T, Takano, M, Echida, Y and Nitta, K (2010). Suppression of renal fbrosis by galectin-1 in high glucose-treated renal epithelial cells. Exp Cell Res 316: 3282-3291.
20. Lim, MJ, Ahn, J, Yi, JY, Kim, MH, Son, AR, Lee, SL et al. (2014). Induction of galectin-1 by TGF-β1 accelerates fbrosis through enhancing nuclear retention of Smad2. Exp Cell Res 326: 125-135.
21. Pichavant, C, Aartsma-Rus, A, Clemens, PR, Davies, KE, Dickson, G, Takeda, S et al. (2011). Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 19: 830-840.
22. Moxley, RT 3rd, Pandya, S, Ciafaloni, E, Fox, DJ and Campbell, K (2010). Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for management. J Child Neurol 25: 1116-1129.
23. Berardi, E, Annibali, D, Cassano, M, Crippa, S and Sampaolesi, M (2014). Molecular and cell-based therapies for muscle degenerations: a road under construction. Front Physiol 5: 119.
24. Ruegg, UT, Nicolas-Métral, V, Challet, C, Bernard-Hélary, K, Dorchies, OM, Wagner, S et al. (2002). Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. Neuromuscul Disord 12 Suppl 1: S155-S161.
25. Shieh, PB (2013). Muscular dystrophies and other genetic myopathies. Neurol Clin 31: 1009-1029.
26. Tinsley, JM, Potter, AC, Phelps, SR, Fisher, R, Trickett, JI and Davies, KE (1996). Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature 384: 349-353.
27. Amenta, AR, Yilmaz, A, Bogdanovich, S, McKechnie, BA, Abedi, M, Khurana, TS et al. (2011). Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci USA 108: 762-767.
28. Burkin, DJ, Wallace, GQ, Milner, DJ, Chaney, EJ, Mulligan, JA and Kaufman, SJ (2005). Transgenic expression of {alpha}7{beta}1 integrin maintains muscle integrity, increases regenerative capacity, promotes hypertrophy, and reduces cardiomyopathy in dystrophic mice. Am J Pathol 166: 253-263.
29. Weisleder, N, Takizawa, N, Lin, P, Wang, X, Cao, C, Zhang, Y et al. (2012). Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med 4: 139ra85.
30. Sonnemann, KJ, Heun-Johnson, H, Turner, AJ, Baltgalvis, KA, Lowe, DA and Ervasti, JM (2009). Functional substitution by TAT-utrophin in dystrophin-defcient mice. PLoS Med 6: e1000083.
31. Mercado, ML, Amenta, AR, Hagiwara, H, Rafi, MS, Lechner, BE, Owens, RT et al. (2006). Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20: 1724-1726.
32. Amenta, AR, Creely, HE, Mercado, ML, Hagiwara, H, McKechnie, BA, Lechner, BE et al. (2012). Biglycan is an extracellular MuSK binding protein important for synapse stability. J Neurosci 32: 2324-2334.
33. Rooney, JE, Gurpur, PB and Burkin, DJ (2009). Laminin-111 protein therapy prevents muscle disease in the mdx mouse model for Duchenne muscular dystrophy. Proc Natl Acad Sci USA 106: 7991-7996.
34. Marshall, JL, Chou, E, Oh, J, Kwok, A, Burkin, DJ and Crosbie-Watson, RH (2012). Dystrophin and utrophin expression require sarcospan: loss of α7 integrin exacerbates a newly discovered muscle phenotype in sarcospan-null mice. Hum Mol Genet 21: 4378-4393.
35. Sioud, M, Mobergslien, A, Boudabous, A and Fløisand, Y (2011). Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins. Int J Oncol 38: 385-390.
36. Ruegg, UT (2013). Pharmacological prospects in the treatment of Duchenne muscular dystrophy. Curr Opin Neurol 26: 577-584.
37. McDonald, CM, Henricson, EK, Abresch, RT, Florence, J, Eagle, M, Gappmaier, E et al.; PTC124-GD-007-DMD Study Group. (2013). The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study. Muscle Nerve 48: 357-368.
38. Henricson, E, Abresch, R, Han, JJ, Nicorici, A, Goude Keller, E, de Bie, E et al. (2013). The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. PLoS Curr 5:.
39. Brooke, MH, Fenichel, GM, Griggs, RC, Mendell, JR, Moxley, R, Florence, J et al. (1989). Duchenne muscular dystrophy: patterns of clinical progression and effects of supportive therapy. Neurology 39: 475-481.
40. Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L et al.; DMD Care Considerations Working Group. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 9: 177-189.
41. Bushby, K, Finkel, R, Birnkrant, DJ, Case, LE, Clemens, PR, Cripe, L et al.; DMD Care Considerations Working Group. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
42. Heydemann, A and McNally, E (2009). NO more muscle fatigue. J Clin Invest 119: 448-450.
43. Angelini, C and Tasca, E (2012). Fatigue in muscular dystrophies. Neuromuscul Disord 22 Suppl 3: S214-S220.
44. Sussman, M (2002). Duchenne muscular dystrophy. J Am Acad Orthop Surg 10: 138-151.
45. Tamma, R, Annese, T, Capogrosso, RF, Cozzoli, A, Benagiano, V, Sblendorio, V et al. (2013). Effects of prednisolone on the dystrophin-associated proteins in the blood-brain barrier and skeletal muscle of dystrophic mdx mice. Lab Invest 93: 592-610.
46. Al-Salam, S and Hashmi, S (2014). Galectin-1 in early acute myocardial infarction. PLoS One 9: e86994.
47. Wuebbles, RD, Sarathy, A, Kornegay, JN and Burkin, DJ (2013). Levels of α7 integrin and laminin-α2 are increased following prednisone treatment in the mdx mouse and GRMD dog models of Duchenne muscular dystrophy. Dis Model Mech 6: 1175-1184.
48. Amalftano, A and Chamberlain, JS (1996). The mdx-amplifcation-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. Muscle Nerve 19: 1549-1553.
49. Wolff, AV, Niday, AK, Voelker, KA, Call, JA, Evans, NP, Granata, KP et al. (2006). Passive mechanical properties of maturing extensor digitorum longus are not affected by lack of dystrophin. Muscle Nerve 34: 304-312.
50. Rooney, JE, Welser, JV, Dechert, MA, Flintoff-Dye, NL, Kaufman, SJ and Burkin, DJ (2006). Severe muscular dystrophy in mice that lack dystrophin and alpha7 integrin. J Cell Sci 119(Pt 11): 2185-2195.
51. Rooney, JE, Gurpur, PB, Yablonka-Reuveni, Z and Burkin, DJ (2009). Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy. Am J Pathol 174: 256-264.
52. Song, WK, Wang, W, Sato, H, Bielser, DA and Kaufman, SJ (1993). Expression of alpha 7 integrin cytoplasmic domains during skeletal muscle development: alternate forms, conformational change, and homologies with serine/threonine kinases and tyrosine phosphatases. J Cell Sci 106 (Pt 4): 1139-1152.
53. Rooney, JE, Knapp, JR, Hodges, BL, Wuebbles, RD and Burkin, DJ (2012) Laminin-111 protein therapy reduces muscle pathology and improves viability of a mouse model of merosin-defcient congenital muscular dystrophy. Am J Pathol 180: 1593-1602.
54. Giordano, C, Mojumdar, K, Liang, F, Lemaire, C, Li, T, Richardson, J et al. (2015). Toll-like receptor 4 ablation in mdx mice reveals innate immunity as a therapeutic target in Duchenne muscular dystrophy. Hum Mol Genet 24: 2147-2162.